Skip to main content

Hemophilia Treatment Drugs Market Estimated to Record Highest CAGR by 2026

Hemophilia Treatment Drugs Market - Snapshot

The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.
Request Sample Of Report -   https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1900
hemophilia treatment industry
The global hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Treatment, education, and support are provided by medical experts at these HTCs. Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.
Request the Coronavirus Impact Analysis on this Markets -   https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1900
The global hemophilia treatment drugs market has been segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the recombinant coagulation factor concentrates segment is projected to account for significant share of the market during the forecast period. New recombinant pipeline agents and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), are expected to gain market share during the forecast period. However, some products such as CSL-689 (phase II/III for hemophilia A and hemophilia B) are likely to account for small market share, as these are positioned as on-demand treatments in a market that is increasingly moving toward prophylaxis.
In terms of disease, the global hemophilia treatment drugs market has been classified into hemophilia A, hemophilia B, and others. The hemophilia A segment accounted for major share of the global hemophilia treatment drugs market in 2017. According to the Centers for Disease Control and Prevention (CDC), the exact number of people living with hemophilia globally is not known; however, hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. In terms of distribution channel, the global hemophilia treatment drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held major market share in 2017. The segment is likely to account for leading share of the market during the forecast period.
Buy _ Research Report Now -   https://www.transparencymarketresearch.com/checkout.php?rep_id=1900&ltype=S
In terms of region, the global hemophilia treatment drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for major shares of the global hemophilia treatment drugs market in 2017 and the trend is likely to continue from 2018 to 2026. High rate of immigration from tropical regions, increase in health care budgets by governments, and government initiatives to promote hemophilia treatment contributed to the leading shares of these regions. Asia Pacific is projected to be the most attractive market for hemophilia treatment drugs during the forecast period. The market in Asia Pacific is expected to expand at a high CAGR from 2018 to 2026 due to large number of hemophilia patients opting for recombinant coagulation factor concentrates in developing countries such as India and China. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.
Prominent players operating in the global hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi. Shire plc accounted for the largest market share in 2017. The company’s dominance of the market is due to its broad product portfolio, extensive geographical presence, and aggressive acquisition strategies. Shire plc strengthened its market position by acquiring Baxalta in June 2016. Baxalta is a key player in the rare diseases and other specialized disorders segments.
Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline. However, F. Hoffmann-La Roche, a new entrant in the hemophilia treatment drugs market, is expected to outperform Novo Nordisk during the forecast period. Pfizer held the third largest share of the hemophilia treatment drugs market in 2017.

More Trending Reports by Transparency Market Research –   https://www.prnewswire.com/news-releases/vitamin-d-testing-market-to-rise-from-us519-mn-valuation-in-2018-to-us877-mn-in-2027-increasing-awareness-about-test-benefits-to-improve-adoption-rate-notes-tmr-301007435.html

Comments

Post a Comment

Popular posts from this blog

Angioplasty Balloons & Stents Market Research Report | Forecast Until 2027

Complications with Existing Treatments to Drive Innovations The healthcare sector is no stranger to innovations and technological advancements. Research and development activities continue to improve the efficacy of treatments and bring forward new therapies to treat a range of diseases. Over the past couple of decades, minimally invasive procedures have gained a great amount of popularity within the healthcare sector. A similar trend can be observed within the angioplasty balloons & stents market as the adoption of minimally invasive procedures is on the rise, particularly among patients who have been diagnosed with coronary heart diseases or experienced a heart attack. Request Sample Of Report –   https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5627 At present, healthcare experts are focusing on minimizing the complications involved with the percutaneous coronary intervention (PCI) by leveraging the benefits of technology that conti...
Post a Comment
Read more

Autoimmune Disease Diagnostics Market Analysis and Forecast up to 2023

Autoimmune Disease Diagnostics Market – Snapshot When immune system attacks the body mistakenly, then the resulting condition is known as autoimmune disease. Some of the autoimmune diseases are found more commonly in certain ethnicities than others. A case in point is high prevalence of lupus amongst the Hispanic and African-American group of people rather than Caucasians. The global autoimmune disease diagnostics market is estimated to make substantial gains due to rising incidences of autoimmune diseases across the globe. Request Sample Of Report –    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5351 Some of the autoimmune diseases such as lupus and multiple sclerosis run within families. In that case, the family members will inherit vulnerability to the autoimmune illness that runs in the family but might not necessarily be affected by it. Increased Prevalence of Autoimmune Diseases to Spell Growth of the Market Many of the auto...
Post a Comment
Read more

Analysis of COVID-19 Collagen Peptide and Gelatin Market

Collagen Peptide and Gelatin Market: Overview According to Transparency Market Research’s latest report on the global collagen peptide and gelatin market for the historical period  2017–2018  and forecast period  2019–2027 , increase in commercialization of novel collagen-based drug delivery systems and rise in social awareness about personal well-being are projected to drive the global collagen peptide and gelatin market According to the report, the global collagen peptide and gelatin market was valued at  US$ 5,976.9 Mn  in  2018  and is projected to expand at a CAGR of  8.7%  from  2019  to  2027 To know the scope of our report  Get a Sample  on Collagen Peptide and Gelatin Market Increase in social awareness about personal well-being and rigorous research and development activities in regenerative medicine and wound healing: Key Drivers Major factors driving the collagen peptide application in nutrac...
Post a Comment
Read more